YCT-529 is an oral retinoic acid receptor alpha (RARα) antagonist currently under investigation as a novel non-hormonal male contraceptive agent. By selectively inhibiting RARα, the compound works to temporarily… Read more
YCT-529 is an oral retinoic acid receptor alpha (RARα) antagonist currently under investigation as a novel non-hormonal male contraceptive agent. By selectively inhibiting RARα, the compound works to temporarily suppress spermatogenesis, offering a potential path for reversible male contraception. Pharmaceutical laboratories involved in the development and characterization of this agent rely on high-quality reference standards to ensure accurate analytical results. This category includes the parent drug alongside essential related compounds, such as the stable isotope labelled YCT-529-d6 and the degradation-related N-nitroso YCT-529 impurity. These materials are critical for researchers performing impurity profiling, method validation, and pharmacokinetic studies. Using these precise analytical standards allows for rigorous quality control throughout the drug development process, facilitating reliable quantification and identification of the parent drug and its related substances in complex matrices.